|Bid||0.2450 x 0|
|Ask||0.2600 x 0|
|Day's Range||0.2450 - 0.2600|
|52 Week Range||0.2200 - 0.9900|
|Beta (5Y Monthly)||1.97|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Growth now expected to exceed 500% from fiscal Q4 2020 to fiscal Q1 2021KELOWNA, BC / ACCESSWIRE / October 22, 2020 / Lexaria Bioscience Corp.
(OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in oral drug delivery platforms, is pleased to announce that it is receiving its first-ever granted patent in Europe related to its DehydraTECHTM technology.
Company Raises Commitment to Antiviral Research with Launch of Rodent Antiviral Drug Delivery Study with Potential COVID-19 ApplicationsKELOWNA, BC / ACCESSWIRE / September 29, 2020 / Lexaria Bioscience Corp.